A Novel Role for Raloxifene Nanomicelles in Management of Castrate Resistant Prostate Cancer
Figure 7
Morphologies and viability of PC3 tumor spheroids after 15 days of treatment with free raloxifene or SMA-Ral. Representative pictures of tumor spheroids were taken following treatment with free raloxifene or SMA-Ral at 2, 5, and 10 μM or controls (DMSO or SMA) (a). Tumor spheroid viability was measured by the activity of acid phosphatase (b). .